![Daniel Bach](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daniel Bach
Directeur/Membre du Conseil chez
Touchstone Innovations Investment Management Ltd.
Profil
Daniel Bach is currently a Director at Touchstone Innovations Investment Management Ltd. and a Non-Executive Director at Crescendo Biologics Ltd. He is also a Partner & Life Sciences at IP Group Plc, a Board Member at CytoKi Pharma ApS, and a Board Member at Vandria SA. Previously, he was a Director at Akamis Bio Ltd. in 2018, a Non-Executive Director at TopiVert Ltd., a Director at Minoryx Therapeutics SL, an Associate at Index Ventures SA from 2010 to 2013, a Managing Partner at Aravis AG from 2014 to 2015, and a Partner at NanoDimension Management Ltd. He holds a doctorate degree from the University of Barcelona and an MBA from Escuela de Organización Industrial.
Postes actifs de Daniel Bach
| Sociétés | Poste | Début |
|---|---|---|
Touchstone Innovations Investment Management Ltd.
 Touchstone Innovations Investment Management Ltd. Investment ManagersFinance IIIM is an active manager which invests in technology businesses based on intellectual property from Imperial College. The company also invests in companies that have been through the incubation process managed by the Imperial Innovations' New Ventures team. The firm leads or co-leads investment rounds in technology companies across all stages of development in the healthcare, energy, environment and emerging technology sectors. Companies seeking first round funding and beyond are expected to have demonstrated that they have recruited of an experienced CEO and CTO, have a functioning board including an experienced Chairman and at least one non-executive director appointed by IIIM, have financial controls and responsible financial management, have resolved initial intellectual property technical risk, have a clear, credible and commercial business plan and have identified a location for the company to achieve full independence IIIM works toward exits through trade sales, mergers or IPOs. | Directeur/Membre du Conseil | 01/01/2016 |
Crescendo Biologics Ltd.
 Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in the development of new medicines based on antibody fragment technology | Directeur/Membre du Conseil | - |
IP Group Plc /Venture Capital/
 IP Group Plc /Venture Capital/ Investment ManagersFinance IP Group invests in companies located in the United Kingdom, United States and Australia. The firm targets companies operating in the fileds of life sciences, deeptech and cleantech. It provides financing for early stage capital requirements. | Private Equity Investor | - |
Vandria SA
 Vandria SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops small molecule mitophagy inducers to treat age-related and chronic diseases | Directeur/Membre du Conseil | - |
CytoKi Pharma ApS
 CytoKi Pharma ApS Miscellaneous Commercial ServicesCommercial Services Provides biotechnological research and development services | Directeur/Membre du Conseil | - |
Anciens postes connus de Daniel Bach
| Sociétés | Poste | Fin |
|---|---|---|
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Operates as a clinical-stage oncology company that engages in development of tumor gene therapies | Directeur/Membre du Conseil | 30/04/2018 |
TopiVert Ltd.
 TopiVert Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company developing medicines for the treatment of chronic inflammatory diseases of gastrointestinal (GI) tract and the eye | Directeur/Membre du Conseil | 12/03/2018 |
Aravis AG
 Aravis AG Investment ManagersFinance Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations. | Private Equity Investor | 31/12/2015 |
Index Ventures SA
 Index Ventures SA Investment ManagersFinance Index Ventures invests companies across the globe. The firm target companies operating across a broad range of sectors and industries. It provides financing for seed, early and growth stage capital requirements. | Analyste en capital-investissement | 31/12/2013 |
| ░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | - |
Formation de Daniel Bach
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
82
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Index Ventures SA
Index Ventures SA Investment ManagersFinance Index Ventures invests companies across the globe. The firm target companies operating across a broad range of sectors and industries. It provides financing for seed, early and growth stage capital requirements. | Finance |
University of Barcelona
 University of Barcelona Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Escuela de Organización Industrial
 Escuela de Organización Industrial Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aravis AG
Aravis AG Investment ManagersFinance Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations. | Finance |
NanoDimension Management Ltd.
 NanoDimension Management Ltd. Investment ManagersFinance NanoDimension Management invests in companies located in the United States and Europe. The firm focuses on the technology sector. It provides for early and later stage companies. | Finance |
Touchstone Innovations Investment Management Ltd.
Touchstone Innovations Investment Management Ltd. Investment ManagersFinance IIIM is an active manager which invests in technology businesses based on intellectual property from Imperial College. The company also invests in companies that have been through the incubation process managed by the Imperial Innovations' New Ventures team. The firm leads or co-leads investment rounds in technology companies across all stages of development in the healthcare, energy, environment and emerging technology sectors. Companies seeking first round funding and beyond are expected to have demonstrated that they have recruited of an experienced CEO and CTO, have a functioning board including an experienced Chairman and at least one non-executive director appointed by IIIM, have financial controls and responsible financial management, have resolved initial intellectual property technical risk, have a clear, credible and commercial business plan and have identified a location for the company to achieve full independence IIIM works toward exits through trade sales, mergers or IPOs. | Finance |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in the development of new medicines based on antibody fragment technology | Commercial Services |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Operates as a clinical-stage oncology company that engages in development of tumor gene therapies | Health Technology |
TopiVert Ltd.
TopiVert Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company developing medicines for the treatment of chronic inflammatory diseases of gastrointestinal (GI) tract and the eye | Health Technology |
IP Group Plc /Venture Capital/
IP Group Plc /Venture Capital/ Investment ManagersFinance IP Group invests in companies located in the United Kingdom, United States and Australia. The firm targets companies operating in the fileds of life sciences, deeptech and cleantech. It provides financing for early stage capital requirements. | Finance |
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Develops pharmaceutical products | Health Technology |
CytoKi Pharma ApS
CytoKi Pharma ApS Miscellaneous Commercial ServicesCommercial Services Provides biotechnological research and development services | Commercial Services |
Vandria SA
Vandria SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops small molecule mitophagy inducers to treat age-related and chronic diseases | Health Technology |
